Boston appeal against J&J award denied
This article was originally published in Clinica
The US Supreme Court has declined to hear Boston Scientific's appeal over the $703m in damages it has to pay for infringing a Johnson & Johnson coronary stent patent. The news dealt another blow to Boston's stock value, which slipped a further 7% yesterday to close at $10.33 per share. On September 30, a US district court in Delaware awarded J&J $1.2bn in damages against Boston and Medtronic. Boston took the brunt of the damages, while Medtronic was ordered to pay the $521m. The ruling was a culmination of an eight-year court battle between the three companies over the Palmaz balloon expandable stent patent, which is owned by J&J.